Literature DB >> 31513374

Antibiotic-Based Conjugates Containing Antimicrobial HLopt2 Peptide: Design, Synthesis, Antimicrobial and Cytotoxic Activities.

Natalia Ptaszyńska1, Katarzyna Gucwa1,2, Katarzyna Olkiewicz1, Anna Łȩgowska1, Joanna Okońska1, Jarosław Ruczyński1, Agata Gitlin-Domagalska1, Dawid Dȩbowski1, Sławomir Milewski2, Krzysztof Rolka1.   

Abstract

Recent studies have shown that modified human lactoferrin 20-31 fragment, named HLopt2, possesses antibacterial and antifungal activity. Thus, we decided to synthesize and evaluate the biological activity of a series of conjugates based on this peptide and one of the antimicrobials with proven antibacterial (ciprofloxacin, CIP, and levofloxacin, LVX) or antifungal (fluconazole, FLC) activity. The drugs were covalently connected to the peptide via amide, methylenecarbonyl moieties, or a disulfide bridge. The antibacterial and antifungal activities were evaluated under Clinical and Laboratory Standard Institute (CLSI) recommended conditions or in a low-salt brain-heart infusion diluted medium (BHI1/100). Results showed that conjugation of the peptide with the drug increased its antimicrobial activity up to 4-fold. Under CLSI-recommended conditions, all the compounds revealed rather low efficiency. Among conjugates, the highest antibacterial activity was recorded for the CIP-Cys-S-S-HLopt2-NH2 (III). In BHI1/100, which had lower differentiating properties, all of the conjugates revealed low MIC and MMC (minimum inhibitory and microbicidal concentrations) values. The disulfide bridge used as a linker in the most active conjugate (III) upon incubation with S. aureus cells is reduced, releasing constituent peptide and CIP-Cys. In addition, we showed that its fluorescently labeled analogue and constituent peptide are able to be internalized into both C. albicans and S. aureus cells. Moreover, the invaluable advantage of the presented conjugates was their low toxicity to mammalian cells and very low hemolytic activity. The current research can form a solid basis for further in vivo studies and drug development.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31513374     DOI: 10.1021/acschembio.9b00538

Source DB:  PubMed          Journal:  ACS Chem Biol        ISSN: 1554-8929            Impact factor:   5.100


  5 in total

1.  New Peptide Based Fluconazole Conjugates with Expanded Molecular Targets.

Authors:  Wioletta Brankiewicz; Joanna Okońska; Katarzyna Serbakowska; Jan Lica; Marek Drab; Natalia Ptaszyńska; Anna Łęgowska; Krzysztof Rolka; Piotr Szweda
Journal:  Pharmaceutics       Date:  2022-03-23       Impact factor: 6.525

2.  Conjugates of Ciprofloxacin and Levofloxacin with Cell-Penetrating Peptide Exhibit Antifungal Activity and Mammalian Cytotoxicity.

Authors:  Natalia Ptaszyńska; Katarzyna Gucwa; Katarzyna Olkiewicz; Mateusz Heldt; Marcin Serocki; Anna Stupak; Dorota Martynow; Dawid Dębowski; Agata Gitlin-Domagalska; Jan Lica; Anna Łęgowska; Sławomir Milewski; Krzysztof Rolka
Journal:  Int J Mol Sci       Date:  2020-06-30       Impact factor: 5.923

3.  Targeted Delivery of Miconazole Employing LL37 Fragment Mutant Peptide CKR12-Poly (Lactic-Co-Glycolic) Acid Polymeric Micelles.

Authors:  Takeshi Mori; Miyako Yoshida; Mai Hazekawa; Daisuke Ishibashi; Yoshiro Hatanaka; Rie Kakehashi; Makoto Nakagawa; Toshihiro Nagao; Miki Yoshii; Honami Kojima; Rio Uno; Takahiro Uchida
Journal:  Int J Mol Sci       Date:  2021-11-08       Impact factor: 5.923

Review 4.  The multifaceted nature of antimicrobial peptides: current synthetic chemistry approaches and future directions.

Authors:  Bee Ha Gan; Josephine Gaynord; Sam M Rowe; Tomas Deingruber; David R Spring
Journal:  Chem Soc Rev       Date:  2021-07-05       Impact factor: 54.564

Review 5.  Antimicrobial Susceptibility Testing of Antimicrobial Peptides to Better Predict Efficacy.

Authors:  Derry K Mercer; Marcelo D T Torres; Searle S Duay; Emma Lovie; Laura Simpson; Maren von Köckritz-Blickwede; Cesar de la Fuente-Nunez; Deborah A O'Neil; Alfredo M Angeles-Boza
Journal:  Front Cell Infect Microbiol       Date:  2020-07-07       Impact factor: 5.293

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.